1. EnvisionTEC wins FDA nod for 3D printing E-Denture material
EnvisionTEC announced in a June 30 press release that it has received FDA approval for its E-Denture material for 3D printing dentures. The company already has the E-Dent 100 and 400 materials approved for the printing of restorations that simulate teeth. The new approval makes EnvisionTEC the only 3D printing company worldwide that has a complete digital denture workflow solution. E-Denture will have a limited distribution in the third quarter and will be available in four natural shades.
2. Life Spine launches Osseo-Loc product line
Life Spine has commercially launched additions to its Osseo-Loc spinal implant family, according to a July 3 press release. The company has added the ProLift Expandable PLIF/TLIF Spacer System and TiBOW Expandable TLIF Spacer System to its Osseo-Loc line offering of titanium surface treated implants. Osseo-Loc is a surface treatment that helps create a unique osteophylic surface architecture for bone on-growth. It promotes mineralization of implants while also negating challenges that come with surface treated implants. With its native titanium grain structured material, the Osseo-Loc surface treatment is designed to optimize intervertebral stability.
3. Zebra Medical Vision inks AI deal with Indian image provider Telerad
Zebra Medical Vision announced in a July 5 press release that it has entered a partnership with Telerad Tech to bring Zebra Medical Vision’s cloud-based deep learning analytics engine to more than 20 countries and 150 healthcare organizations. Zebra Medical Vision already has its imaging solutions implemented in hospitals across Europe and the U.S. With Telerad Tech’s collaboration, Zebra Medical Vision will be able to expand its solutions to India, broader Asia and Africa.
4. SpineGuard, Adin Dental Implant Systems sign licensing agreement for dental implantology
SpineGuard and Adin Dental Implant Systems have signed an exclusive licensing agreement for the use of SpineGuard’s Dynamic Surgical Guidance (DSG) technology in dental implantology, according to a July 3 press release. The deal also includes technology transfers, product development support, milestones and royalty payments between the two companies. The companies suggest that the DSG technology will be used for three major dental applications with a total of around 8 million dental procedures.
5. SpineWave launches Leva interbody AF device
SpineWave announced in a June 29 press release that it has commercially launched its Leva AF Interbody Device for anterior lumbar inter body fusion (ALIF) procedures. The company plans to fully launch the product in September 2017. With its all-titanium construction, modular anterior plates and a selection of bone screws for vertebral body fixation, the Leva AF Interbody Device has a large graft chamber that helps with copious grafting with graft-to-endplate contact within the device.
6. NeoTract touts 5-year UroLift data
NeoTract has announced the data from its UroLift System study that measured the safety and effectiveness of the system for treating symptomatic benign prostatic hyperplasia, according to a June 30 press release. The five-year study suggests that the UroLift System has reached maturity as a standard of care for enlarged prostates. The UroLift System has been proven to be a highly tolerable, minimally-invasive procedure; rapid reduction of symptoms post-procedure with sexual function preservation; sustained effect with International Prostate Symptom Score of 36% and peak urinary flow rate of 44% improvement from baseline; a quality of life improvement of 50% over a five-year period; and a low surgical pretreatment rate of 2-3% per year, according to NeoTract. A total of 430 men aged 50 years or older participated in the study.
7. InVivo Therapeutics adds new site to spinal study
InVivo Therapeutics announced in a June 29 press release that it has added UCHealth Memorial Hospital in Colorado Springs, Colo. as a clinical site for its Inspire Study. The addition of the hospital brings the number of participating clinical sites to 32 sites throughout the U.S.